TNF and rheumatoid arthritis: The TNF-α inhibitors infliximab and adalimumab are also approved for the treatment of RA; however, other biological DMARDs such as tocilizumab seem to be more effective in the treatment of disease symptoms and drug adherence for patients [74,75].